FILE PHOTO: Exact Sciences Laboratories building is shown in Madison, Wisconsin, U.S., March 28, 2019. REUTERS/Howard Schneider
(Reuters) – Cancer diagnostics company Exact Sciences Corp (EXAS.O) is in advanced negotiations to buy healthcare company Genomic Health Inc (GHDX.O) for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.
A deal could be announced as early as next week but the talks could still be delayed or fall apart altogether, according to the report, which cited people familiar with the matter.
Exact Sciences and Genomic Health did not respond immediately to a Reuters request for comment on Saturday.
Reporting by Kanishka Singh in Bengaluru; Editing by Sonya Hepinstall
Source: Reuters.com © 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.Follow us: